Search Results 521-530 of 18379 for alopecia

  1. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

    excluding alopecia. - Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within 28 days of starting the study drug ...

  2. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

    Adverse events due to previous anti-tumor therapy have not recovered to ≤ CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤ CTCAE Grade 2.

  3. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) - Mayo Clinic

    Participants with alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency treated with ≤10 mg daily ...

  4. Betamethasone dipropionate (topical application route) - Side effects & dosage - Mayo Clinic

    Betamethasone topical spray is used to treat adults with mild to moderate plaque psoriasis. This medicine is a corticosteroid (cortisone-like medicine or ...

  5. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

    ... alopecia and =< grade 2 neuropathy, which are allowed; Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion ...

  6. A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma - Mayo Clinic

    ... alopecia. Taxane Naive Patients Only: No prior exposure to taxane therapy of any duration for angiosarcoma. Taxane Pre-treated Patients Only: Prior taxane ...

  7. Publications - Timothy D. Malouff, M.D. - Mayo Clinic

    Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS One. 2013; 8 (7):e69368 Epub 2013 July 19. View PubMed. PST-20566501. Home ...

  8. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas - Mayo Clinic

    ... alopecia not requiring systemic treatment, conditions not expected to recur in the absence of an external trigger. Patients with a history of organ ...

  9. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

    Any persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 drug-related toxicity (except alopecia, erectile impotence ...

  10. Study of MK-8242 Alone and in Combination with Cytarabine in Participants with Acute Myelogenous Leukemia (P07649) - Mayo Clinic

    Recovered from the effects of any prior surgery, radiotherapy or anti-neoplastic treatment, with the exception of alopecia; Must be able to swallow, retain ...